In late March 2026, UiPath held a special call and reported fourth-quarter fiscal 2026 revenue of US$481 million, 14% year-over-year growth, alongside its first full year of GAAP profitability with US$57 million in operating income and a US$500 million stock buyback authorization.
At the same time, UiPath deepened its push into agentic AI with offerings like Agentic ERP launched with Deloitte, even as investors weighed CEO transition news and competitive pressure from large AI providers, creating debate about how effectively the company can turn its technology roadmap into durable monetization.
We’ll now examine how UiPath’s first full-year GAAP profitability and expanded agentic AI offerings may reshape its existing investment narrative.
AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10b in market cap – there’s still time to get in early.
To own UiPath, you need to believe that its automation and agentic AI platform can translate rising AI deployment into recurring, profitable revenue, despite slowing growth expectations and tough competition from large AI providers. The key near term catalyst is whether new AI offerings and stabilized net new ARR can support the company’s fiscal 2027 revenue guidance, while the biggest risk is that intensifying AI and orchestration competition limits ARR expansion and pressures margins.
The expanded Deloitte alliance around Agentic ERP looks especially important here, because it puts UiPath’s Maestro and agentic capabilities directly into complex ERP workflows where enterprises often face long sales cycles, strict governance and significant budget scrutiny. How effectively this and other new vertical solutions in areas like financial crime and healthcare convert into higher value AI ARR will influence whether the recent profitability milestone can evolve into a more durable, high quality earnings profile.
Yet even with these positives, investors should be aware that competitive pressure in agentic AI could still…
Read the full narrative on UiPath (it’s free!)
UiPath’s narrative projects $2.1 billion revenue and $147.2 million earnings by 2029.
Uncover how UiPath’s forecasts yield a $13.80 fair value, a 47% upside to its current price.
PATH 1-Year Stock Price Chart
Before this news, the most optimistic analysts were modeling about US$2.1 billion of revenue and US$204 million of earnings by 2029, which is far more upbeat than the more cautious view that competition could hold back Maestro and agent adoption, so it is worth recognizing how differently you might assess UiPath’s potential from here.
Explore 10 other fair value estimates on UiPath – why the stock might be worth just $13.80!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include PATH.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com